Immuneering Corp (IMRX)
1.555
+0.02
(+1.63%)
USD |
NASDAQ |
May 02, 15:02
Immuneering Shareholders Equity (Quarterly): 90.58M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 90.58M |
September 30, 2023 | 104.02M |
June 30, 2023 | 115.10M |
March 31, 2023 | 97.79M |
December 31, 2022 | 109.85M |
September 30, 2022 | 121.89M |
June 30, 2022 | 133.59M |
Date | Value |
---|---|
March 31, 2022 | 144.06M |
December 31, 2021 | 155.98M |
September 30, 2021 | 158.29M |
June 30, 2021 | -35.19M |
March 31, 2021 | 29.58M |
December 31, 2020 | -22.48M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-35.19M
Minimum
Jun 2021
158.29M
Maximum
Sep 2021
92.54M
Average
109.85M
Median
Dec 2022
Shareholders Equity (Quarterly) Benchmarks
Geron Corp | 247.95M |
SELLAS Life Sciences Group Inc | -7.976M |
Elicio Therapeutics Inc | 11.37M |
Vistagen Therapeutics Inc | 123.28M |
ADMA Biologics Inc | 135.21M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 102.58M |
Total Liabilities (Quarterly) | 12.01M |